Several clinical trials have or are being performed testing the safety and efficacy of different strains of oncolytic viruses (OV) for malignant cancers. OVs represent either naturally occurring or genetically engineered strains of viruses that exhibit relatively selective replication in tumor cells. Several types of OV have been derived from herpes simplex virus 1 (HSV1). Tumor oncolysis depends on the processes of initial OV infection of tumor, followed by subsequent propagation of OV within the tumor itself. The role of the immune responses in these processes has not been extensively studied. On the contrary, effects of the immune response on the processes of wild-type HSV1 infection and propagation in the central nervous system have been studied and described in detail. The first line of defense against a wild-type HSV1 infection in both naive and immunized individuals is provided by innate humoral (complement, cytokines, chemokines) and cellular (macrophages, neutrophils, NK cells, gd T cells, and interferon-producing cells) responses. These orchestrate the lysis of virions and virus-infected cells as well as provide a link to effective adaptive immunity. The role of innate defenses in curtailing the oncolytic effect of genetically engineered HSV has only recently been studied, but several of the same host responses appear to be operative in limiting anticancer effects by the replicating virus. The importance of this knowledge lies in finding avenues to modulate such initial innate responses, in order to allow for increased oncolysis of tumors while minimizing host toxicity. Gene Therapy (2003) 10, 983-990.
Introduction
Oncolytic viruses (OV) are either naturally occurring or genetically engineered viruses that possess relatively selective replicative and lytic abilities for tumor cells. 1 Several OVs have been derived from herpes simplex virus 1 (HSV1). In preclinical trials in animal models of tumors, encouraging biologic effects have been reported, leading to phase I clinical trials in humans afflicted by cancer. 2, 3 Such phase I trials have revealed the relative safety of this approach, yet signs of efficacy remain to be determined. Nevertheless, knowledge that wild-type HSV1 can provoke a fairly brisk immune response in humans and animals always remains a concern. Such responses can lead to encephalitis, meningitis, hepatitis, and keratitis. 4 Serological studies have revealed that 50-80% of humans possess neutralizing activity against the virus. 4 This neutralizing activity can be partially protective in inhibiting spread of a replicating virus. In phase I trials, although, there were no apparent differences in toxicities among treated individuals who possessed neutralizing immunity to HSV.
In spite of the phase I findings, it is known that in both immune and naive individuals, wild-type HSV-1 infection will induce initial antiviral innate defenses followed by adaptive, acquired responses. The major differences in such responses between immune and naive individuals reside in the rapidity and magnitude of the acquired response. Innate immunity possesses two primary functions. First, it directly destroys pathogenic microorganisms. Second, it determines the type and initiation of adaptive responses. 5 Innate immune responses against wild-type HSV1 include: (1) activation of the complement cascade, 6, 7 (2) activation of macrophages, recruitment, activation, and maturation of NK cells, CD4+ CD11c-type 2 DC precursors, 8, 9 and gd, extrathymicderived, T cells, [10] [11] [12] and (3) generation and secretion of a variety of cytokines and chemokines that orchestrate the above activities. [13] [14] [15] [16] [17] [18] [19] [20] The objective of these responses is to limit the initial infection of a tissue, abrogate further propagation of the virus, and begin maturation of dendritic and/or dendritic-like cells that will then activate antigenspecific T cells as well the maturation of B cells to begin production of high-affinity, high-avidity IgG. 21 Like many other viruses, virulent forms of HSV-1 have evolved several molecular mechanisms to evade and escape such host responses. These include: (1) binding and inactivation of complement molecules (C3b, C5, and Properdin) by glycoprotein C, present on the viral envelope, 22, 23 (2) binding and inactivation of immunoglobulin by glycoproteins E and I, present on the viral envelope, [24] [25] [26] [27] (3) escape from presentation of viral antigens in the context of MHC by expression of the viral ICP47 that blocks peptide transport across the endoplasmic reticulum via the TAP transporter, 28 (4) inhibition of dendritic cell maturation, 29 and (5) inhibition of induction and activity of type 1 interferons. 30, 31 Although much is known about the interactions governing virulent, wild-type HSV1 infection in the central nervous system and other organs, it is not clear if this knowledge applies to the situation of a genetically modified, attenuated oncolytic HSV replicating within a tumor. If initial innate antiviral responses operate effectively against a replicating OV within a tumor, one might expect limited anticancer effects (Figure 1) . Conversely, if a replicating OV remains capable of effectively evading such immune responses or if such immune responses were blunted, one might expect enhanced anticancer effects from viral oncolysis, although toxicity to normal tissues may also arise. These scenarios are further complicated by the findings that active immune responses against virally infected tumors may actually produce a cytotoxic T-cell response, reminiscent of a vaccination effect, thus leading to increased tumor therapy. 32 In this review, we will focus on the initial innate host responses against wild-type HSV1, consisting of humoral (complement, cytokines, and chemokines) and cellular responses (macrophages, NK cells, subsets of T cells). We will expand our discussion by reviewing experimental results from our laboratory related to relevance of such responses in the context of genetically engineered HSV OV replicating within a tumor. Finally, we will provide a perspective on further areas of investigative research.
Complement and its interactions with wild-type HSV-1 infection of the central nervous system
The complement cascade represents one of the potent initial lines of defense against pathogenic microorganisms 33 ( Figure 2 ). It involves a variety of serum proteins, each catalyzing proteolytic activation of additional proteins, which lead to the final formation of the membrane attack complex (MAC), responsible for lysis of microorganisms and infected cells. Some of the proteolytic products also function in recruitment of inflammatory cells and in opsonization by macrophages.
Initiation of complement activity begins upon antigen recognition by one molecule of IgM or by several molecules of IgG ('classical' pathway). This activates the first component of complement (C1q), which in turn leads to proteolysis of subsequent components (C4 and C2). The proteolysis and activation of subsequent components (C3, C5, C6-C9) is then catalyzed by each member of this cascade. Other pathways of complement activation exist: a self-activated pathway (the 'alternative' pathway) and a pathway (the 'lectin', 'MBP', or 'MBL' pathway) that depends on recognition by serum mannose-binding protein (MBP, also known as mannosebinding lectin -MBL) of sugar moieties present on the surface of viruses and bacteria. It should be noted that isoforms of MBP exist, which may provide additional complexity to the mechanisms of complement activation. [34] [35] [36] [37] Since the 1980s it has been known that wild-type, virulent forms of HSV1 can evade complement's antiviral action, primarily because one of the viral surface glycoproteins (gC) binds to, and inactivates, the C3 component (found at the convergence of all three pathways of complement activation) as well as other components (C5 and properdin). 22, 38 This effect though is variable: some strains of wild-type HSV1 evaded complement better than others. 39 In fact, some of the most widely used strains of HSV (such as KOS or F) have been passaged in the laboratory for decades using fetal calf or bovine serum that is relatively depleted of complement. Experimentally, we ( Figure 3 ) and others 27 have found that only one-third of HSV1 KOS strain virus (a common laboratory strain) survives incubation with human serum compared to 90% of NS strain (a virulent clinical isolate). As expected, a gC-null mutant derived from NS was quite sensitive to human serum: only 0.33% Figure 1 Differential propagation/spread of oncolytic virus within a tumor, dependent on active or blunted innate immune response. The oncolytic virus (OV) is represented by the red hexagon. With a blunted innate immune response, the OV is able to infect tumor cells and then replicate (ie generate viral progeny) that will sequentially infect other tumor cells. As discussed in this review, an active innate response consisting of complement and innate immune cells will limit the ability of OVs to infect initially and subsequently propagate throughout the tumor. . Initiation can also proceed through the calcium-independent alternative pathway or through the calcium-dependent lectin pathway, by recognition of mannose moieties on antigens by mannose-binding protein (MBP -also known as mannose-binding lectin). Components specific to each pathway are: C1q,r,s, C2, and C4 for the classical pathway, Properdin, Factor B, and D for the alternative pathway, and MASP1,2 (but also C2 and C4) for the lectin pathway. Convergence on C3 to generate C3 proteolytic products, which in turn activate C5 and the final components of the MAC (membrane attack complex) responsible for virolysis and cytolysis are depicted. Proteolytic products of C3 and C5 also function in neutrophil chemotaxis and as opsonins for macrophages.
Effects of immunity on HSV
H Wakimoto et al remained capable of cell infection after incubation (ref. 27 and Figure 3 ). Overall rat serum was much more potent than human serum in inactivating viruses for reasons that may have to do with different pathways of complement activation, as explained below. Comparison of the nucleotide sequences of gC from these viruses revealed several nucleotide polymorphisms with aminoacid substitutions in complement-interacting domains, suggesting that such polymorphisms may be responsible for strain differences in complement evasion ( Figure 4 ). The ability of some strains of HSV1 (such as NS) to evade complement action may contribute to their relative virulence and provides an effective mechanism for wild-type virus' ability to initiate an infection without being curtailed by initial host responses.
Complement and its interactions with oncolytic HSVnfecting brain tumors
Serum complement plays an important role in the inactivation of HSV in the bloodstream, 7 but serum complement may be limited in concentration or activity in peripheral tissues. 6 Monocyte-produced C3 may be essential for complement activity in the skin (Carroll and Knipe, unpublished results) . Therefore, what is the role of complement, then, in limiting infection of a tumor by HSV OV? We were confronted with this question, when we attempted administration of an HSV OV in the arterial system of rats harboring brain tumors. Although OV administration in preclinical and clinical models is routinely carried out as a direct intratumoral inoculation, systemic delivery through the circulation has the potential for delivering the therapeutic agent to multiple regions of a brain tumor or to multiple brain tumors. However, infection of brain tumors by intravascular OV can be fairly inefficient. Several reasons may account for this: (1) biodistribution studies of intravascular HSV OV show that most of the dose ends up in the hepatic system 40, 41 and, in fact, intravascular delivery of an HSV OV to treat multiple metastatic colorectal cancer foci in mouse livers is very efficient, [42] [43] [44] [45] [46] (2) the bloodbrain-and blood-brain tumor-barrier impede access to the central nervous system, 47, 48 and (3) serum/blood exposure inactivates the OV. 49 In fact, several components of serum have been reported to bind to viruses (Table 1) . Most importantly, immunoglobulin binding to virus and virus-infected cells has been reported to inhibit further HSV infection by virus neutralization and cell lysis through antibody-dependent cellular cytotoxicity, 25 opsonization, and complement activation of classical pathway. 7 We found that HSV recombinants derived from strains KOS, F, and 17 + were inactivated by the serum of rats (either athymic or immunocompotent animals) in a dose-dependent fashion. Sera from humans, marmosets, and mice also inactivated such viruses, but not as potently as rat serum (3 and Wakinoto et al 50 ). Pharmacological depletion of complement with cobra venom factor (CVF) reversed serum's antiviral activity and enhanced the efficiency of in vivo infection of brain tumors by intravascular OV. 51 Serum from mice with homozygous genetic defects in the C3 or C4 components of complement was not as effective in inhibiting OV infection as serum from parental mice. These data thus indicate that complement plays a major role in limiting infection of brain tumors by an intravascular HSV OV.
As mentioned, we also found species-specific differences not only in the potency but also in pathways of complement activation against the OV. 50 In rats, both immunoglobulin and MBL-activated complement against the oncolytic virus, while in mice only MBL was relevant and in humans only immunoglobulin seemed to play a role. The finding of a role for immunoglobulin did not necessarily imply a need for HSV-specific immunity: in fact, sera from animals and humans without pre-existing immunity to the virus still inhibited viral activity. Such sera still contained natural IgM and IgG, which bound to the OV in vitro, as assayed by ELISA and Western blots. (an OV with deletions in the viral genes encoding for ICP34.5 and insertion of lacZ into UL39, derived from F strain), wild-type NS and KOS strain and a glycoprotein C-deleted (gC-null) NS HSV were incubated with human or rat serum (diluted 1:2) for 1 h at 371C. The mix was then added onto Vero cells and the number of plaques were counted to determine how many virus had survived the serum incubation. Figure 4 Comparison of gC amino-acid sequences between strain NS and strain hrR3-KOS HSVs. The diagram represents the amino-acid sequences with relevant domains as illustrated in Lubinski et al. 23 SIG designates the signal sequence, gC domains responsible for binding to C5/Properdin and Herparan sulfate (amino acids 33-123) are shown, as well as the four C3b-complement binding domains (I, IV, II, and III). Non-conserved polymorphisms were found in amino acids 132, 300, and 421, each located within the C3-binding domains. The significance of such substitutions remains under investigation, but is suggestive of a reason why hrR3-KOS may not evade complement as well as NS (see Figure 3) .
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The hypothesis that natural Igs may be responsible for complement activation against the OV in rats and humans leads one to speculate which epitope(s) are being recognized. A variety of natural Igs have been described. For instance, a human natural IgG that recognizes the Gala1-3Gal epitope present on the surface of mammalian cells (except for humans and old-world primates) is responsible for the hyperacute, complementmediated, rejection of xenotransplants as well as for lysis of retroviruses and lymphocytic choriomeningitis viruses. [52] [53] [54] [55] However, experimental evidence suggests that this or a related natural Ig is unlikely to be responsible for the observed effects. 49 Natural IgMs reactive against exposed membrane C-terminal sequences 56 
Propagation of wild-type HSV-1 in the central nervous system.
The host response to an HSV-1 infection in the nervous system may also determine how many cells become infected by replicating viruses. While complement may have a role in inhibiting infection of central nervous system cells by virus within the circulation, its role in curtailing propagation of virus from nervous system sites, such as cornea, is less apparent. 7 Nonetheless, several other innate mechanisms may be operative in this context and, in fact, both humoral factors and cellular responses have been investigated. The former consist of cytokines and chemokines, while the latter consist of macrophages, gd, T-cell receptor positive T cells, CD4 +
CD11c
À type 2 DC precursors, and NK cells. A number of cytokines have been shown to elicit protective effects by limiting wild-type HSV1 infection in vitro and/or in vivo (Table 2) . Interferons a/b are perhaps the most powerful antiviral cytokines and endow cells with a state of relative nonpermissivity for productive infection by HSV. HSV possesses at least three mechanisms by which it attempts to resist the effects of type 1 interferons: (1) HSV blocks the nuclear accumulation of interferon regulatory factor 3, which is needed for the activation of transcription of type 1 IFN genes, (2) HSV blocks the phosphorylation of stat1 that is induced by interferons, 59 and (3) HSV promotes the dephosphorylation of eIF-2a 60 so as to reverse the effects of doublestranded RNA and interferons on the dsRNA-dependent kinase, PKR. 61 Despite these attempts to subvert the type 1 interferon responses, evidence for the in vivo role of type 1 interferons in restricting HSV infection and spread has come from studies of mice with homozygous genetic defects in mediators of interferon signaling. 30, 61 Two such pathways involve stimulation of 2 0 5 0 -oligoadenylate synthase (OAS) activity, which in turn activates RNAseL leading to the inhibition of viral replication and activation of double-stranded RNA-dependent protein kinase (PKR), which inhibits translation, also leading to the inhibition of viral replication. Interestingly, PKR activation has been linked to the activation of the proinflammatory NF-kB pathway as well as to iNOS production in response to influenza virus. [62] [63] [64] The role of interferon g in limiting HSV infection has been debated, with some authors advocating a relatively minor role, 61 while others finding that it is an important antiviral mediator. 16, 65 It is produced by activated macrophages and extrathymic, gd-TCR+ T cells in response to viral infections. 20 IFNg can directly inhibit HSV replication as well as stimulate the production of iNOS, whose generation of nitric oxide has been shown to be a powerful inhibitor of HSV replication. 17, 19 The cytokines interleukin-15 and -18 may also modulate innate and adaptive immune responses to HSV. In humans, IL-15 is produced by activated peripheral blood mononuclear cells and it is responsible for the activation of NK cells against HSV-1.
14,18 IL-18 is produced by activated macrophages, and it induces IFNg production by mouse helper T cells and NK cells. 15 Similarly, macrophage-produced TNFa is an important initial mediator of the inflammatory response, and inhibition of its expression would appear to be a necessary step for efficient viral infection and replication. 20 The chemokine, RANTES/CCL5, produced by activated macrophages in response to HSV infection attracts monocytes and NK cells to the site of infection and may also provide a link to adaptive immune responses. 13 Innate cellular responses against wild-type HSV1, such as macrophages, NK cells, gd T cells, and CD4 + CD11c
À type 2 DC cells may also be relevant in determining neuroinvasiveness. For instance, gd T cells produce IFNg, which in turn stimulates macrophages to produce TNFa and iNOS. The enzymatic product of the latter, nitric oxide, has been shown to be detrimental to HSV1 replication. 17, 19, 20, 27 CD4 + CD11c À type 2 DC are identical to blood-borne natural interferon a/b producing cells, which generate enormous amounts of interferons in response to viral (including HSV1) infection. 8, 9 The protective antiviral effects of interferon have been discussed earlier. 61 They also produce TNFa, which may function in an autocrine fashion to differentiate them into mature DCs with subsequent triggering of Tcell-mediated immunity. Therefore, the convergence to sites of HSV infection of a variety of innate immune cells and of their cytokine products provides another potent line of defense against wild-type HSV1 infection and spread in the central nervous system. Recent studies have shown that HSV can activate Tolllike receptor signaling through the TLR-2 receptor (Knipe and Finberg, manuscript in preparation). Therefore, HSV infection can activate the expression and release of cytokines, including IL6, IL-8, and IL-12 from macrophages and dendritic cells. In the human central nervous system, monocyte-derived microglial cells have been found to express several types of TLRs, while TLR-2 and TLR-3 were expressed in astrocytes and oligodendrocytes. 66 These findings, thus, provide interesting implications related to innate defense mechanisms in the central nervous system that might impede HSV1 dissemination.
Propagation of oncolytic HSV in central nervous system tumors
Despite the relative wealth of information related to innate responses against wild-type HSV1 in the nervous system, little, if any, evidence has been reported regarding innate cytokine/chemokine and cellular responses in response to oncolytic HSV infection of brain tumors.. In the course of our studies, though, we have become convinced that such responses must be operative, although the nature of humoral factors and cells involved remains to be identified. This conviction is based primarily on two findings: (1) in animals without pre-existing immunity to OV, there is rapid upregulation of cytokine mRNAs (such as interferons, TNFa, IL-15, IL-18) and of some of their mediators, such as iNOS, in peripheral blood mononuclear cells as well as in brain tumors, within hours of exposure to OV (Wakimoto and Chiocca, submitted) and (2) in naive (ie without preexisting immunity to HSV1) animals, propagation of an OV HSV is significantly facilitated within a 4-day time span after administration of an immunosuppressive agent such as cyclophosphamide ( Figure 5 ). The rapidity of these responses, which clearly precedes the onset of anti-HSV1 neutralizing immunity, 49 likely indicates an effect at the level of the innate immune response.
The upregulation of cytokines and iNOS within hours of OV inoculation into a brain tumor reveals how the innate cellular immune response will rapidly mobilize to confront the anticancer agent. Such a response bears striking similarities to responses previously described for wild-type HSV1 infection in central nervous system, as discussed earlier. It thus is not unreasonable to hypothesize that, left unchecked, this innate host response would limit OV propagation within the brain tumor and, perhaps, anticancer effects.
Interestingly, CPA has been used to stimulate neuroinvasion of wild-type HSV1 in the central nervous system of animals. CPA leads to a rapid decrease in peripheral blood mononuclear cells in animals, with less than onethird of such cells remaining 48 h after drug administration. We have found that remaining PBMCs are also impaired in their capacity to generate mRNAs for interferons, IL-15, IL-18, and TNFa. Whether this is related to impaired recruitment of macrophages, NK cells, gd T cells, and/or interferon-producing cells to the infected tumor is still not known, but interestingly levels of IFNg, iNOS, and TNFa mRNAs were found to be decreased in infected tumors and brain surrounding tumor 60 h after CPA treatment. Therefore, it appears primarily that innate humoral and cellular responses to an oncolytic virus within a tumor may resemble those observed with wild-type HSV1 in the context of central nervous system invasion, but clearly additional evidence needs to be accumulated to confirm this. Nonetheless, it will be interesting to try to define if there is one particular set of antiviral responses that is responsible for limiting OV survival in tumors, because pharmacological means could be then employed to inhibit these in a fashion that is more selective than the use of pleiotropic immunosuppressants.
Cyclophosphamide -a 'booster' for OV infection of and propagation within brain tumors
The effects of cyclophosphamide in boosting the oncolytic activity of HSV OV strains argues for a significant role of innate responses in modulating OV infection and ability to kill tumor cells. Initially, when we were studying delivery of HSV OV through the arterial circulation, we found that complement depletion using CVF facilitated the infection of tumors in the brain. 51 As discussed previously, though, this was not sufficient to allow for OV propagation within infected tumors. This suggested that complement had a minimal role in inhibiting OV dissemination within a tumor perhaps due to its low concentrations within normal nervous tissue 67 and due to the expression by human brain tumors of factors that downmodulate complement activity. 68, 69 Instead, when CPA was used, both increases in initial infection of tumors and in subsequent propagation of OV within tumors were observed. 49, 51 Therefore, CPA was not only functioning in a manner similar to CVF (ie allowing initial infection of tumor cells), but in addition was performing additional functions to allow for OV propagation in a manner dissimilar to CVF. With regard to the first effect, serum prepared from animals, pretreated with CPA, did not inactivate OV as well as serum from untreated rats. These results resembled those observed with serum from CVF-treated rats. The CPAlabile, innate antiviral activity was also found to be present in humans.
To further characterize this CPA-modulated innate activity, we determined that, while complement activity was not affected in animal blood after CPA treatment, the levels of IgM had decreased to less than half of the original values. In fact, anti-IgM treatment of rat serum Figure 5 OV replication propagation within a brain tumor, 4 days after CPA administration. Athymic rats with human glioma xenografts were injected intra-arterially with hrR3, an OV that expresses the lacZ transgene, 2 days after CPA immunosuppression. Two days after OV injection, some animals were killed and their brains with tumors were stained for lacZ expression. A section containing a single lacZ-positive viral plaque within the tumor is shown. At 4 days after OV injection, additional animals were killed and their entire tumor was positive for lacZ, indicative of OV propagation within the tumor. This led to tumor regression and involution, as assayed by the day 8 time point. In animals not treated with CPA, this process is not observed or is observed rarely. 49, 51 . Effects of immunity on HSV H Wakimoto et al reversed antiviral activity in vitro in a dose-dependent fashion. 49 Therefore, these findings suggested that CPA, by decreasing the availability of innate IgM, blunted complement's activity against the OV thus leading to increased infection. In addition, once the OV infected the tumor, CPA limited PBMC antiviral cytokine responses thus allowing for increased propagation ( Figure 6 ). Increased OV propagation mediated by CPA led to increased anticancer effects as evidenced by improved survival of animals with brain tumors 49 (Wakimoto et al, submitted).
Summary and future perspectives
Although transient iatrogenic suppression of host innate immunity by the use of complement inhibitors or CPA seems to provide an enhancement of viral infection and/or propagation that leads to improved efficacy of OV-based tumor therapy, questions related to mechanisms of cells and cytokines involved arise. Further clinical application of this approach also will require appropriate safety testing in HSV-sensitive primate models to address the toxicity the approach might present to the host and to normal tissues. 70 Several important questions arise from our studies, such as (1) the identification of HSV epitopes recognized by natural immunoglobulin, (2) the regulation of viral propagation inside tumors by components of the host innate immune response, and (3) the linkage of innate responses to adaptive responses and whether the tumor environment modifies such responses. The latter is particularly important, because some studies have not detected detrimental effects on HSV OV-mediated tumor responses in animals with pre-existing immunity to HSV. [71] [72] [73] These studies though did not study initial infection, propagation, and survival of OV within tumor, rather focused on long-term biologic effects such as animal survival from tumor, decrease in tumor volumes, and responses to tumor rechallenges. Therefore, it is possible that results from these studies may be because of the long-term endowment of additional immunogenicity to tumors by a viral infection (by adaptive, memory T cells), akin to the results described in Toso et al, 32 more than effects on the initial stages of OV infection and propagation, studied by us. [49] [50] [51] Further elucidation of mechanisms of the early immune responses to OV is likely to provide refinements in OV anticancer strategy and to define if transient immunosuppressive measures will help or hinder the desired biologic effects. Figure 6 A model of OV infection and propagation within brain tumors. An HSV virion, OV, or vector, when delivered via the circulation, has to: (1) infect a tumor cell and, (2) propagate the infection to additional tumor cells. The process of infection will be impeded, in part by recognition of viral antigens by innate Igs (in rats and humans) or by MBP (in mice and rats), 50 which will activate the complement cascade and limit the number of OV available for initial infection. Depletion of complement with CVF or of Igs with CPA can be employed to inhibit this antiviral activity. Once the OV has infected tumor, additional rounds of infection (propagation) will be curtailed by innate immune cells and by antiviral cytokines. CPA can be used to decrease rapidly the number of innate immune cells and their production of antiviral cytokines (Wakimoto and Chiocca, submitted).
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